Loading…

Vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in an Egyptian population

Purpose The aim of this study was to investigate the role of −1154 guanine (G)>adenine (A) and +405 G>cytosine (C) vascular endothelial growth factor (VEGF) gene polymorphisms as possible risk factors for neovascular age-related macular degeneration (nAMD) and to evaluate their role in patient...

Full description

Saved in:
Bibliographic Details
Published in:Delta Journal of Ophthalmology 2023-07, Vol.24 (3), p.178-185
Main Authors: Marwa Abdel Kareem Mohamed Aly, Hanan Salah El Deen Mahrous, Lubna Mohamed Ibrahim Desouky, Karim Mahmoud Nabil
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 185
container_issue 3
container_start_page 178
container_title Delta Journal of Ophthalmology
container_volume 24
creator Marwa Abdel Kareem Mohamed Aly
Hanan Salah El Deen Mahrous
Lubna Mohamed Ibrahim Desouky
Karim Mahmoud Nabil
description Purpose The aim of this study was to investigate the role of −1154 guanine (G)>adenine (A) and +405 G>cytosine (C) vascular endothelial growth factor (VEGF) gene polymorphisms as possible risk factors for neovascular age-related macular degeneration (nAMD) and to evaluate their role in patients’ response to anti-VEGF therapy. Patients and methods The study included 50 nAMD patients and 64 age and sex-matched healthy volunteers. Polymerase chain reaction-restriction fragment length polymorphism was performed to assess the VEGF −1154 G>A and +405 G>C polymorphisms in relation to AMD. Results Hypertension was reported in 40 (80%) cases compared to 14 (21.9%) of the controls, with a statistically significant difference (P < 0.001). Heart disease was also reported more significantly in patients (13 = 26%) than in controls (7 = 10.9%), P = 0.036. In addition, smoking was detected in 39 cases (78%) compared to 10 (15.6%) controls, a statistically significant difference (P < 0.001). Molecular analysis of VEGF −1154 G>A and VEGF +405 G>C gene polymorphisms yielded nonstatistically significant difference between cases and control groups. Assessment of genotype frequency of VEGF −1154 among responders and nonresponders yielded nonstatistically significant difference. However, genotype frequency of VEGF +405 among responders and nonresponders revealed a statistically significant difference, with the GG genotype associated with better response to anti-VEGF therapy (61.1% responders versus 28.6% nonresponders according to visual acuity and optical coherence tomography parameters, P = 0.037). Conclusion Smoking, hypertension, and heart disease were critical risk factors for the development of AMD. The VEGF +405 G>C genotype was found to be an important predictor for response to anti-VEGF therapy.
doi_str_mv 10.4103/djo.djo_64_22
format article
fullrecord <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8c0b8e78b4e945ac8a98d93ee1d2a7a9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_8c0b8e78b4e945ac8a98d93ee1d2a7a9</doaj_id><sourcerecordid>oai_doaj_org_article_8c0b8e78b4e945ac8a98d93ee1d2a7a9</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3112-1b3b31f5d6d1648f85bebf11f16d1497b88a091139fa37e154f0901ecca7b1f33</originalsourceid><addsrcrecordid>eNotj81qwzAQhEVpoSHNsXe9gFOt5R_pWELaBgK9tL2albVyFBzLyColb1-n6WGZZeZjYBh7BLEuQMgnewzr-ZqqaPL8hi1yoUVWKFnesgUAiExDLe_Zapq8EaWopaikXLD0hVP73WPkNNiQDtR77HkXw086cIdtCpF3NBAfQ38-hTge_HSaOA6WY0dZpB4TWX7Ca4mlCxwx-TBwP8wc33bnMfn5GcM4M5fkgd057Cda_euSfb5sPzZv2f79dbd53metBMgzMNJIcKWtLFSFcqo0ZByAg9kodG2UQqEBpHYoa4KycPNooLbF2oCTcsl2114b8NiM0Z8wnpuAvvkzQuwajMm3PTWqFUZRrUxBuiixVaiV1ZIIbI41avkLN_ZuWg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in an Egyptian population</title><source>DOAJ Directory of Open Access Journals</source><creator>Marwa Abdel Kareem Mohamed Aly ; Hanan Salah El Deen Mahrous ; Lubna Mohamed Ibrahim Desouky ; Karim Mahmoud Nabil</creator><creatorcontrib>Marwa Abdel Kareem Mohamed Aly ; Hanan Salah El Deen Mahrous ; Lubna Mohamed Ibrahim Desouky ; Karim Mahmoud Nabil</creatorcontrib><description>Purpose The aim of this study was to investigate the role of −1154 guanine (G)&gt;adenine (A) and +405 G&gt;cytosine (C) vascular endothelial growth factor (VEGF) gene polymorphisms as possible risk factors for neovascular age-related macular degeneration (nAMD) and to evaluate their role in patients’ response to anti-VEGF therapy. Patients and methods The study included 50 nAMD patients and 64 age and sex-matched healthy volunteers. Polymerase chain reaction-restriction fragment length polymorphism was performed to assess the VEGF −1154 G&gt;A and +405 G&gt;C polymorphisms in relation to AMD. Results Hypertension was reported in 40 (80%) cases compared to 14 (21.9%) of the controls, with a statistically significant difference (P &lt; 0.001). Heart disease was also reported more significantly in patients (13 = 26%) than in controls (7 = 10.9%), P = 0.036. In addition, smoking was detected in 39 cases (78%) compared to 10 (15.6%) controls, a statistically significant difference (P &lt; 0.001). Molecular analysis of VEGF −1154 G&gt;A and VEGF +405 G&gt;C gene polymorphisms yielded nonstatistically significant difference between cases and control groups. Assessment of genotype frequency of VEGF −1154 among responders and nonresponders yielded nonstatistically significant difference. However, genotype frequency of VEGF +405 among responders and nonresponders revealed a statistically significant difference, with the GG genotype associated with better response to anti-VEGF therapy (61.1% responders versus 28.6% nonresponders according to visual acuity and optical coherence tomography parameters, P = 0.037). Conclusion Smoking, hypertension, and heart disease were critical risk factors for the development of AMD. The VEGF +405 G&gt;C genotype was found to be an important predictor for response to anti-VEGF therapy.</description><identifier>ISSN: 1110-9173</identifier><identifier>EISSN: 2090-4835</identifier><identifier>DOI: 10.4103/djo.djo_64_22</identifier><language>eng</language><publisher>Wolters Kluwer Medknow Publications</publisher><subject>anti-vegf therapy ; egypt ; gene polymorphisms ; neovascular age-related macular degeneration ; vascular endothelial growth factor</subject><ispartof>Delta Journal of Ophthalmology, 2023-07, Vol.24 (3), p.178-185</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,2095,27903,27904</link.rule.ids></links><search><creatorcontrib>Marwa Abdel Kareem Mohamed Aly</creatorcontrib><creatorcontrib>Hanan Salah El Deen Mahrous</creatorcontrib><creatorcontrib>Lubna Mohamed Ibrahim Desouky</creatorcontrib><creatorcontrib>Karim Mahmoud Nabil</creatorcontrib><title>Vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in an Egyptian population</title><title>Delta Journal of Ophthalmology</title><description>Purpose The aim of this study was to investigate the role of −1154 guanine (G)&gt;adenine (A) and +405 G&gt;cytosine (C) vascular endothelial growth factor (VEGF) gene polymorphisms as possible risk factors for neovascular age-related macular degeneration (nAMD) and to evaluate their role in patients’ response to anti-VEGF therapy. Patients and methods The study included 50 nAMD patients and 64 age and sex-matched healthy volunteers. Polymerase chain reaction-restriction fragment length polymorphism was performed to assess the VEGF −1154 G&gt;A and +405 G&gt;C polymorphisms in relation to AMD. Results Hypertension was reported in 40 (80%) cases compared to 14 (21.9%) of the controls, with a statistically significant difference (P &lt; 0.001). Heart disease was also reported more significantly in patients (13 = 26%) than in controls (7 = 10.9%), P = 0.036. In addition, smoking was detected in 39 cases (78%) compared to 10 (15.6%) controls, a statistically significant difference (P &lt; 0.001). Molecular analysis of VEGF −1154 G&gt;A and VEGF +405 G&gt;C gene polymorphisms yielded nonstatistically significant difference between cases and control groups. Assessment of genotype frequency of VEGF −1154 among responders and nonresponders yielded nonstatistically significant difference. However, genotype frequency of VEGF +405 among responders and nonresponders revealed a statistically significant difference, with the GG genotype associated with better response to anti-VEGF therapy (61.1% responders versus 28.6% nonresponders according to visual acuity and optical coherence tomography parameters, P = 0.037). Conclusion Smoking, hypertension, and heart disease were critical risk factors for the development of AMD. The VEGF +405 G&gt;C genotype was found to be an important predictor for response to anti-VEGF therapy.</description><subject>anti-vegf therapy</subject><subject>egypt</subject><subject>gene polymorphisms</subject><subject>neovascular age-related macular degeneration</subject><subject>vascular endothelial growth factor</subject><issn>1110-9173</issn><issn>2090-4835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNotj81qwzAQhEVpoSHNsXe9gFOt5R_pWELaBgK9tL2albVyFBzLyColb1-n6WGZZeZjYBh7BLEuQMgnewzr-ZqqaPL8hi1yoUVWKFnesgUAiExDLe_Zapq8EaWopaikXLD0hVP73WPkNNiQDtR77HkXw086cIdtCpF3NBAfQ38-hTge_HSaOA6WY0dZpB4TWX7Ca4mlCxwx-TBwP8wc33bnMfn5GcM4M5fkgd057Cda_euSfb5sPzZv2f79dbd53metBMgzMNJIcKWtLFSFcqo0ZByAg9kodG2UQqEBpHYoa4KycPNooLbF2oCTcsl2114b8NiM0Z8wnpuAvvkzQuwajMm3PTWqFUZRrUxBuiixVaiV1ZIIbI41avkLN_ZuWg</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Marwa Abdel Kareem Mohamed Aly</creator><creator>Hanan Salah El Deen Mahrous</creator><creator>Lubna Mohamed Ibrahim Desouky</creator><creator>Karim Mahmoud Nabil</creator><general>Wolters Kluwer Medknow Publications</general><scope>DOA</scope></search><sort><creationdate>20230701</creationdate><title>Vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in an Egyptian population</title><author>Marwa Abdel Kareem Mohamed Aly ; Hanan Salah El Deen Mahrous ; Lubna Mohamed Ibrahim Desouky ; Karim Mahmoud Nabil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3112-1b3b31f5d6d1648f85bebf11f16d1497b88a091139fa37e154f0901ecca7b1f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>anti-vegf therapy</topic><topic>egypt</topic><topic>gene polymorphisms</topic><topic>neovascular age-related macular degeneration</topic><topic>vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marwa Abdel Kareem Mohamed Aly</creatorcontrib><creatorcontrib>Hanan Salah El Deen Mahrous</creatorcontrib><creatorcontrib>Lubna Mohamed Ibrahim Desouky</creatorcontrib><creatorcontrib>Karim Mahmoud Nabil</creatorcontrib><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Delta Journal of Ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marwa Abdel Kareem Mohamed Aly</au><au>Hanan Salah El Deen Mahrous</au><au>Lubna Mohamed Ibrahim Desouky</au><au>Karim Mahmoud Nabil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in an Egyptian population</atitle><jtitle>Delta Journal of Ophthalmology</jtitle><date>2023-07-01</date><risdate>2023</risdate><volume>24</volume><issue>3</issue><spage>178</spage><epage>185</epage><pages>178-185</pages><issn>1110-9173</issn><eissn>2090-4835</eissn><abstract>Purpose The aim of this study was to investigate the role of −1154 guanine (G)&gt;adenine (A) and +405 G&gt;cytosine (C) vascular endothelial growth factor (VEGF) gene polymorphisms as possible risk factors for neovascular age-related macular degeneration (nAMD) and to evaluate their role in patients’ response to anti-VEGF therapy. Patients and methods The study included 50 nAMD patients and 64 age and sex-matched healthy volunteers. Polymerase chain reaction-restriction fragment length polymorphism was performed to assess the VEGF −1154 G&gt;A and +405 G&gt;C polymorphisms in relation to AMD. Results Hypertension was reported in 40 (80%) cases compared to 14 (21.9%) of the controls, with a statistically significant difference (P &lt; 0.001). Heart disease was also reported more significantly in patients (13 = 26%) than in controls (7 = 10.9%), P = 0.036. In addition, smoking was detected in 39 cases (78%) compared to 10 (15.6%) controls, a statistically significant difference (P &lt; 0.001). Molecular analysis of VEGF −1154 G&gt;A and VEGF +405 G&gt;C gene polymorphisms yielded nonstatistically significant difference between cases and control groups. Assessment of genotype frequency of VEGF −1154 among responders and nonresponders yielded nonstatistically significant difference. However, genotype frequency of VEGF +405 among responders and nonresponders revealed a statistically significant difference, with the GG genotype associated with better response to anti-VEGF therapy (61.1% responders versus 28.6% nonresponders according to visual acuity and optical coherence tomography parameters, P = 0.037). Conclusion Smoking, hypertension, and heart disease were critical risk factors for the development of AMD. The VEGF +405 G&gt;C genotype was found to be an important predictor for response to anti-VEGF therapy.</abstract><pub>Wolters Kluwer Medknow Publications</pub><doi>10.4103/djo.djo_64_22</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1110-9173
ispartof Delta Journal of Ophthalmology, 2023-07, Vol.24 (3), p.178-185
issn 1110-9173
2090-4835
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_8c0b8e78b4e945ac8a98d93ee1d2a7a9
source DOAJ Directory of Open Access Journals
subjects anti-vegf therapy
egypt
gene polymorphisms
neovascular age-related macular degeneration
vascular endothelial growth factor
title Vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in an Egyptian population
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T22%3A48%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vascular%20endothelial%20growth%20factor%20gene%20polymorphisms%20and%20age-related%20macular%20degeneration%20in%20an%20Egyptian%20population&rft.jtitle=Delta%20Journal%20of%20Ophthalmology&rft.au=Marwa%20Abdel%20Kareem%20Mohamed%20Aly&rft.date=2023-07-01&rft.volume=24&rft.issue=3&rft.spage=178&rft.epage=185&rft.pages=178-185&rft.issn=1110-9173&rft.eissn=2090-4835&rft_id=info:doi/10.4103/djo.djo_64_22&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_8c0b8e78b4e945ac8a98d93ee1d2a7a9%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3112-1b3b31f5d6d1648f85bebf11f16d1497b88a091139fa37e154f0901ecca7b1f33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true